{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T15:46:32Z","timestamp":1751298392723},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.leukres.2011.12.011","type":"journal-article","created":{"date-parts":[[2012,1,3]],"date-time":"2012-01-03T00:50:34Z","timestamp":1325551834000},"page":"e66-e67","source":"Crossref","is-referenced-by-count":24,"title":["Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index"],"prefix":"10.1016","volume":"36","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppina","family":"Loglisci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Salaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Serrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2011.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.leukres.2007.01.024","article-title":"Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib","volume":"31","author":"Breccia","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.12.011_bib0010","first-page":"110","article-title":"Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy","author":"le Coutre","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2011.12.011_bib0015","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.leukres.2009.01.040","article-title":"The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism","volume":"33","author":"Breccia","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2011.12.011_bib0020","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1200\/JCO.2004.04.217","article-title":"Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment","volume":"22","author":"Breccia","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2011.12.011_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1042\/CS20070122","article-title":"Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet","volume":"114","author":"Hagerkvist","year":"2008","journal-title":"Clin Sci (London)"},{"key":"10.1016\/j.leukres.2011.12.011_bib0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/CS20090348","article-title":"Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes","volume":"118","author":"Mokhtari","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.leukres.2011.12.011_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.leukres.2011.12.011_bib0040","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.10.014","article-title":"Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib","volume":"599","author":"Day","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.leukres.2011.12.011_bib0045","first-page":"116","article-title":"Efficacy and safety of nilotinib in chronic phase (CP) chronic myeloid leukemia (CML) patients (pts) with type 2 diabetes in the ENESTnd trial","author":"Saglio","year":"2010","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100590X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521261100590X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T09:24:50Z","timestamp":1543310690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521261100590X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S014521261100590X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2011.12.011","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}